BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34256839)

  • 1. Progress in molecular feature of smoldering mantle cell lymphoma.
    Jiang P; Desai A; Ye H
    Exp Hematol Oncol; 2021 Jul; 10(1):41. PubMed ID: 34256839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoldering mantle cell lymphoma.
    Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
    Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
    Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
    Jain P; Wang M
    Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.
    Navarro A; Clot G; Royo C; Jares P; Hadzidimitriou A; Agathangelidis A; Bikos V; Darzentas N; Papadaki T; Salaverria I; Pinyol M; Puig X; Palomero J; Vegliante MC; Amador V; Martinez-Trillos A; Stefancikova L; Wiestner A; Wilson W; Pott C; Calasanz MJ; Trim N; Erber W; Sander B; Ott G; Rosenwald A; Colomer D; Giné E; Siebert R; Lopez-Guillermo A; Stamatopoulos K; Beà S; Campo E
    Cancer Res; 2012 Oct; 72(20):5307-16. PubMed ID: 22915760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
    Yi S; Yan Y; Jin M; Bhattacharya S; Wang Y; Wu Y; Yang L; Gine E; Clot G; Chen L; Yu Y; Zou D; Wang J; Phan AT; Cui R; Li F; Sun Q; Zhai Q; Wang T; Yu Z; Liu L; Liu W; Lyv R; Sui W; Huang W; Xiong W; Wang H; Li C; Xiao Z; Hao M; Wang J; Cheng T; Bea S; Herrera AF; Danilov A; Campo E; Ngo VN; Qiu L; Wang L
    J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34882582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.
    Qiu L; Xu J; Tang G; Wang SA; Lin P; Ok CY; Garces S; Yin CC; Khanlari M; Vega F; Medeiros LJ; Li S
    Hum Pathol; 2022 Jan; 119():59-68. PubMed ID: 34767860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
    Isaac KM; Portell CA; Williams ME
    Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
    Deshotels L; Safa FM; Saba NS
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
    Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
    Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Wilson MR; Barrett A; Cheah CY; Eyre TA
    Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX11, a key oncogenic factor in mantle cell lymphoma.
    Beekman R; Amador V; Campo E
    Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index.
    Kimura Y; Sato K; Imamura Y; Arakawa F; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Niino D; Sugita Y; Morito T; Yoshino T; Nakamura S; Ohshima K
    Cancer Sci; 2011 Sep; 102(9):1734-41. PubMed ID: 21609366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
    Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
    Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis.
    Saksena A; Yin CC; Xu J; Li J; Zhou J; Wang SA; Lin P; Tang G; Wang L; Wang M; Miranda RN; Medeiros LJ; Li S
    Hum Pathol; 2019 Jul; 89():71-80. PubMed ID: 31054894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.
    Clot G; Jares P; Giné E; Navarro A; Royo C; Pinyol M; Martín-Garcia D; Demajo S; Espinet B; Salar A; Ferrer A; Muntañola A; Aymerich M; Rauert-Wunderlich H; Jaffe ES; Connors JM; Gascoyne RD; Delabie J; López-Guillermo A; Ott G; Wright GW; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; Beà S; Campo E
    Blood; 2018 Jul; 132(4):413-422. PubMed ID: 29769262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.